Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | AZD2284 |
| Synonyms | |
| Therapy Description |
AZD2284 is a radioconjugate comprising a monoclonal antibody targeting STEAP2 linked to a DOTA chelate and the radionuclide actinium-225, which potentially inhibits tumor growth (Cancer Res (2025) 85 (8_Supplement_1): 4303). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| AZD2284 | AZD-2284|AZD 2284 | AZD2284 is a radioconjugate comprising a monoclonal antibody targeting STEAP2 linked to a DOTA chelate and the radionuclide actinium-225, which potentially inhibits tumor growth (Cancer Res (2025) 85 (8_Supplement_1): 4303). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|